292 related articles for article (PubMed ID: 33964325)
1. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial.
Zapatero A; Álvarez A; Guerrero A; Maldonado X; González San Segundo C; Cabeza MA; Martín de Vidales C; Solé JM; Pedro Olivé A; Casas F; Boladeras A; Vázquez de la Torre ML; Vara S; Calvo FA
Radiother Oncol; 2021 Jul; 160():115-119. PubMed ID: 33964325
[TBL] [Abstract][Full Text] [Related]
2. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
3. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
Kishan AU; Wang X; Sun Y; Romero T; Michalski JM; Ma TM; Feng FY; Sandler HM; Bolla M; Maingon P; De Reijke T; Neven A; Steigler A; Denham JW; Joseph D; Nabid A; Carrier N; Souhami L; Sydes MR; Dearnaley DP; Syndikus I; Tree AC; Incrocci L; Heemsbergen WD; Pos FJ; Zapatero A; Efstathiou JA; Guerrero A; Alvarez A; San-Segundo CG; Maldonado X; Xiang M; Rettig MB; Reiter RE; Zaorsky NG; Ong WL; Dess RT; Steinberg ML; Nickols NG; Roy S; Garcia JA; Spratt DE;
Eur Urol; 2022 Jul; 82(1):106-114. PubMed ID: 35469702
[TBL] [Abstract][Full Text] [Related]
4. Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).
Morris MJ; Mota JM; Lacuna K; Hilden P; Gleave M; Carducci MA; Saad F; Cohn ED; Filipenko J; Heller G; Shore N; Armstrong AJ; Scher HI
Eur Urol Oncol; 2021 Aug; 4(4):543-552. PubMed ID: 34020931
[TBL] [Abstract][Full Text] [Related]
5. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
[TBL] [Abstract][Full Text] [Related]
6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
7. A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer.
Spiegel DY; Hong JC; Oyekunle T; Waters L; Lee WR; Salama JK; Koontz BF
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):834-842. PubMed ID: 30419308
[TBL] [Abstract][Full Text] [Related]
8. Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.
Planas J; Celma A; Placer J; Cuadras M; Regis L; Gasanz C; Trilla E; Salvador C; Lorente D; Morote J
Scand J Urol; 2016 Dec; 50(6):425-428. PubMed ID: 27628623
[TBL] [Abstract][Full Text] [Related]
9. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer.
Nam W; Choi SY; Yoo SJ; Ryu J; Lee J; Kyung YS; Han JH; You D; Jeong IG; Hong JH; Ahn H; Kim CS
Investig Clin Urol; 2018 Jan; 59(1):18-24. PubMed ID: 29333510
[TBL] [Abstract][Full Text] [Related]
11. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
Wang Y; Dai B; Ye DW
Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy.
Shiota M; Endo S; Fujimoto N; Tsukahara S; Ushijima M; Kashiwagi E; Takeuchi A; Inokuchi J; Uchiumi T; Eto M
Urol Oncol; 2020 Nov; 38(11):849.e11-849.e18. PubMed ID: 32712140
[TBL] [Abstract][Full Text] [Related]
13. Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
Int J Biol Markers; 2005; 20(2):119-22. PubMed ID: 16011042
[TBL] [Abstract][Full Text] [Related]
14. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
Nishiyama T
Urol Oncol; 2014 Jan; 32(1):38.e17-28. PubMed ID: 23769268
[TBL] [Abstract][Full Text] [Related]
15. Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.
Kishan AU; Wang X; Seiferheld W; Collette L; Sandler KA; Sandler HM; Bolla M; Maingon P; De Reijke T; Hanks GE; Nickols NG; Rettig M; Drakaki A; Reiter RE; Spratt DE; Kupelian PA; Steinberg ML; King CR
JAMA Oncol; 2019 Jan; 5(1):91-96. PubMed ID: 30326032
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
Shiota M; Takeuchi A; Sugimoto M; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Dec; 35(12):6925-32. PubMed ID: 26637918
[TBL] [Abstract][Full Text] [Related]
17. Testosterone in prostate cancer: the Bethesda consensus.
Djavan B; Eastham J; Gomella L; Tombal B; Taneja S; Dianat SS; Kazzazi A; Shore N; Abrahamsson PA; Cheetham P; Moul J; Lepor H; Crawford ED
BJU Int; 2012 Aug; 110(3):344-52. PubMed ID: 22129242
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.
Kwak L; Ravi P; Armstrong JG; Beckendorf V; Chin JL; D'Amico AV; Dearnaley DP; Di Stasi SM; Gillessen S; Lukka H; Mottet N; Pommier P; Seiferheld W; Sydes MR; Tombal B; Zapatero A; Regan MM; Xie W; Sweeney CJ
J Clin Oncol; 2024 Mar; ():JCO2300762. PubMed ID: 38471051
[TBL] [Abstract][Full Text] [Related]
19. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
[TBL] [Abstract][Full Text] [Related]
20. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
